To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action. This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm. To view information about this, please visit the FAQ. If you have any further questions, please contact us.
Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma
Provider Data DescriptionNCT00079417-D1
Blanks represent missing data or not applicable for analysis. The CONSORT diagram (manuscript Figure 2) can be reconstructed with the variable consort1 through consort4. The dataset contains one line for every patient enrolled on ARET0331. Table 1, Table 2, Figure 3 and the cumulative incidence calculations can be calculated from this data set.
SponsorChildren's Oncology Group
Data ProviderNational Cancer Institute
Partial set or SubsetN/A
Patients in dataset28
# of Patients Control0
# of Patients ExperimentalNA
CDISC StandardNCI standard
Clinical Trials.gov Information
Brief SummaryThis phase III trial is studying how well giving carboplatin and vincristine together with standard local ophthalmic therapy works in treating children with intraocular retinoblastoma. Drugs used in chemotherapy, such as carboplatin and vincristine, work in different ways to stop tumor from dividing so they stop growing or die. It is not yet known whether neoadjuvant chemotherapy combined with standard local ophthalmic therapy is effective in treating intraocular retinoblastoma.